The Readout Loud

350 Odcinki

1. 287: 2023 in review, CEO report cards, and a look at the year ahead

   Opublikowany: 21.12.2023
2. 286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future

   Opublikowany: 14.12.2023
3. 285: CRISPR history, biotech struggles, & a big week for deals

   Opublikowany: 7.12.2023
4. 284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

   Opublikowany: 30.11.2023
5. 283: A CRISPR milestone, algorithms amok, & biotech mixology

   Opublikowany: 16.11.2023
6. From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?

   Opublikowany: 13.11.2023
7. 282: Lilly’s obesity drug, the power of radiation, & a biotech implosion

   Opublikowany: 9.11.2023
8. 281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

   Opublikowany: 2.11.2023
9. 280: ESMO highlights, Roivant's big deal, & biotech VC on the rise

   Opublikowany: 26.10.2023
10. 279: Live from the 2023 STAT Summit

    Opublikowany: 19.10.2023
11. 278: Merger Mondays, Ozempic panic, & CRISPR'd pigs

    Opublikowany: 12.10.2023
12. 277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus

    Opublikowany: 5.10.2023
13. 276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump

    Opublikowany: 28.09.2023
14. 275: A thorny ALS debate at the FDA, and the promise of artificial wombs

    Opublikowany: 21.09.2023
15. 274: Covid’s latest surge, Alnylam at the FDA, & the end of an era

    Opublikowany: 14.09.2023
16. 273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter

    Opublikowany: 7.09.2023
17. 272: Vivek's star turn, leaky drug data, & biotech as family business

    Opublikowany: 24.08.2023
18. 271: Racing for gene therapy, a pioneering approval, & startups in the lurch

    Opublikowany: 18.08.2023
19. 270: Your guide to Wegovy’s blockbuster heart study

    Opublikowany: 10.08.2023
20. 269: Biotech layoffs, eye drug drama, & gene therapy milestones

    Opublikowany: 3.08.2023